Elucidating the exact pharmacological mechanism of motion (MOA) of naturally developing compounds could be difficult. Whilst Tarselli et al. (60) produced the primary de novo synthetic pathway to conolidine and showcased this naturally occurring compound properly suppresses responses to the two chemically induced and inflammation-derived pain, the